β-Glucocerebrosidase (GBA) is the enzyme that degrades glucosylceramide in lysosomes. Defects in GBA that result in overall loss of enzymatic activity give rise to the lysosomal storage disorder Gaucher disease, which is characterized by the accumulation of glucosylceramide in tissue macrophages. Gaucher disease is currently treated by infusion of mannose receptor-targeted recombinant GBA. The recombinant GBA is thought to reach the lysosomes of macrophages, based on the impressive clinical response that is observed in Gaucher patients (type 1) receiving this enzyme replacement therapy. In this study, we used cyclophellitol-derived activity-based probes (ABPs) with a fluorescent reporter that irreversibly bind to the catalytic pocket of GBA, to visualize the active enzymes in a correlative microscopy approach. The uptake of pre-labeled recombinant enzyme was monitored by fluorescence and electron microscopy in human fibroblasts that stably expressed the mannose receptor.
The endogenous active enzyme was simultaneously visualized by in situ labeling with the ABP containing an orthogonal fluorophore. This method revealed the efficient delivery of recombinant GBA to lysosomal target compartments that contained endogenous active enzyme.
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| INTRODUCTION
The lysosomal acid β-glucosidase, β-glucocerebrosidase (GBA, EC 3.2.1.45), is essential to the catabolism of glycosphingolipids in lysosomes as it removes the β-D-glucopyranose group from glucosylceramide. The enzyme encoded by the GBA gene is synthesized as a 497 amino acid protein in the endoplasmic reticulum. While the majority of the lysosomal enzymes are modified with the mannose 6-phosphate recognition marker to mediate their transport from the biosynthetic pathway to the lysosomes, GBA does not contain phosphomannosyl residues. [1] [2] [3] Instead, GBA is routed via a mannose 6-phosphate independent targeting pathway, by binding to the lysosomal membrane protein, LIMP II. 4 LIMP II interacts with newly synthesized GBA at the site of the endoplasmic reticulum. After passage through the Golgi complex, the LIMP II-GBA complex is directed to endosomes and lysosomes, likely through a dileucine-based sorting motif in its C-terminal cytosolic tail. 5, 6 The importance of LIMP II is evident as individuals with LIMP II deficiency develop progressive myoclonic epilepsy with glomerulosclerosis and neurological manifestations, named action myoclonus-renal failure syndrome (AMRF). 7, 8 In AMRF, mutations in the SCARB2 gene encoding LIMP II cause the failure of normally synthesized GBA to interact with LIMP II. As a result, GBA is secreted from the cells, leading to reduced lysosomal levels of the enzyme in various cell types. 4, 7, 9, 10 Mutations in GBA result in a prominent loss of GBA in lysosomes and cause the autosomal recessive lysosomal storage disorder Gaucher disease. 11 Gaucher disease is characterized by the accumulation of the substrate glucosylceramide in tissue macrophages. 12 The clinical manifestations of the disease are remarkably variable, but usually include enlargement of the liver and spleen, infiltration of the bone marrow by storage macrophages, thrombocytopenia, anemia and bone disease, and can include neurological symptoms. Currently approved treatments are substrate reduction therapy aiming to reduce substrate buildup in macrophages and enzyme replacement therapy (ERT), in which human recombinant GBA (hrGBA) is administered intravenously. To mediate uptake by macrophages, hrGBA is modified to expose its mannose moieties, which bind to the mannose receptor (Man-R) present at the surface of these cells. Endocytosis of the Man-R delivers hrGBA to the endo-lysosomal system.
The development of activity-based probes (ABPs) that covalently and irreversibly tag GBA with high sensitivity and almost complete selectivity has allowed the ultra-sensitive visualization of active GBA molecules in vitro and in vivo in cells and organisms. 13 These cyclophellitol-derived ABPs react with the catalytic nucleophile Glu340 of GBA to form an enzyme-substrate complex, linked through an ester bond that is stable under native physiological conditions. When applied to the cell culture medium, the ABPs rapidly enter the cells, a process that appears independent of endocytosis, 13 and bind to the intracellular pools of GBA. The presence of a fluorescent reporter allows the detection by light microscopy. 13 As fluorescence microscopy does not provide information about the underlying ultrastructure, in this study a correlative light and electron microscopy (CLEM) approach was employed to allow the more detailed localization of active GBA. Moreover, the cellular fate of hrGBA following binding to the Man-R was investigated. The uptake of ABP-prelabeled hrGBA was monitored while simultaneously visualizing the endogenous enzyme by using ABPs with different fluorescent reporters. Light microscopy showed colocalization of endocytosed and endogenous GBA, but also distinct punctae for either endocytosed or endogenous enzyme. By CLEM, the endogenous GBA was mainly localized to lysosomes, where it showed substantial overlap with endocytosed hrGBA. Of note, some lysosomes did not appear to be reached by hrGBA during the course of the experiment. In addition, the endocytosed enzyme was detected in earlier compartments of the endo-lysosomal system that showed no detectable endogenous GBA. This method will be valuable in determining the efficiency of ERT for Gaucher disease and potentially other lysosomal storage diseases.
| RESULTS
GBA was readily detected in normal human dermal fibroblasts (NHDFs) by fluorescence microscopy upon in situ labeling with the ABP, MDW941 (Figure 1 ), consistent with previous observations by our lab. 13 Under these conditions, approximately 50% of total GBA was labeled, as determined by GBA activity assays. Pre-incubation with conduritol B epoxide (CBE) for 16 hours prior to the in situ labeling with MDW941, which should block the active site of all available GBA molecules, 14 resulted in no detectable signal ( Figure S1 in Data S1), neither was any signal detected upon dimethyl sulfoxide (DMSO) or CBE incubation in the absence of probe ( Figure S1in Data S1).
These data indicate that the fluorescent signal does not represent unbound, endocytosed probe and is specific to active GBA. Impor- positive punctae contained dextran ( Figure S3 in Data S1).
To identify the endo-lysosomal compartments that accumulated active GBA, a correlative microscopy approach was applied. First, GBA was in situ labeled as in the previous experiments, after which the cells were fixed, gelatin embedded and prepared for electron microscopy according to the Tokuyasu technique. 15 The ultrathin cryosections on grids were first mounted on glass slides with 50% glycerol to allow their imaging by confocal microscopy. This revealed the presence of numerous fluorescent punctae per cell profile ( Figure 2A ). Subsequently, the sections were contrasted and embed- showed low levels of active GBA, but in most cases the signal was below the detection limit ( Figure 2D ,E). These data indicate that the majority of the active GBA molecules in fibroblasts reside in the lysosomes.
To allow the efficient internalization of hrGBA by human fibroblasts, cell lines were generated that stably express the mannose receptor (Man-R) with a C-terminal V5 tag. In this way, the uptake of hrGBA by the modified fibroblasts mimics the mode of uptake by tissue macrophages, which express Man-R at their surface. Fibroblasts that were obtained from a patient homozygous for the nonsense mutation p.W178X 7 contained no detectable levels of LIMP II by Western blotting ( Figure 3A ). As a result, the intracellular level of GBA was significantly reduced. In control fibroblasts, three bands were detected for GBA by Western blotting ( Figure 3A ), that is, the complex glycosylated form, the ER form and the late endosomal/lysosomal form. 16 In the LIMP II −/− cells low levels of the ER form were detected ( Figure 3A ) and the intracellular GBA activity was reduced to approxi- were immunostained for LAMP-1 after the 6 hours-uptake with hrGBA ( Figure S6 in Data S1). There was partial overlap of hrGBA and LAMP-1. Importantly, no signal for MDW933-hrGBA could be visualized after uptake in the presence of mannan, which further suggests that no cross-labeling of endogenous GBA occurred with MDW933.
As expected, endogenous GBA failed to be detected in the LIMP II −/− fibroblasts ( Figure 5 , middle panels). However, uptake of MDW933-labeled hrGBA resulted in a punctate pattern that showed partial overlap with LAMP-1 ( Figure 5 , lower panels, see insets, Figure S2B in Data S1). These data suggest that hrGBA is delivered to late endosomes/lysosomes in the absence of LIMP II.
With CLEM the nature of the various fluorescent punctae could be identified. The uptake of labeled hrGBA was continuous for 6 hours, as shorter incubations did not result in sufficient levels of internalized hrGBA that were detectable by our CLEM method. We anticipated that the hrGBA-containing punctae would represent both early and late compartments of the endo-lysosomal system. Consistent with this prediction, hrGBA was present in endosomes, as well as in lysosomes ( Figure 6A -E). In addition, significant overlap was observed between endocytosed and endogenous GBA in lysosomes ( Figure 6E ). Interestingly, some lysosomes appeared to be negative for endocytosed hrGBA ( Figure 6E ). In agreement with the previous data, no endogenous GBA was detected by CLEM in the LIMP II −/− fibroblasts. However, endocytosed hrGBA was delivered to the endosomes and lysosomes (Figure 7) , suggesting that the absence of LIMP II does not have a major effect on the lysosomal delivery of GBA upon endocytosis.
| DISCUSSION
In this study we have presented a correlative microscopy method that combines the use of ABPs, for the detection of active lysosomal enzyme by fluorescence microscopy, with electron microscopy. This The cyclophellitol-derived ABPs that irreversibly bind to the active site of the lysosomal β-glucosidase GBA, readily penetrate through the cellular membranes, which provides the great benefit that they can be applied to living cells. 13 In our approach, in situ labeling of human fibroblasts with ABP, equipped with a fluorescent tag, was followed by fixation and sample preparation according to the Tokuyasu technique. 15, 17 The ultrathin cryosections were directly imaged for their fluorescent signal by confocal microscopy, without the need of on-section labeling reactions that could increase background signals or influence the sensitivity of detection. The subsequent imaging by electron microscopy provides a relatively straightforward technique to localize the active enzyme to distinct subcellular compartments.
This correlative approach to localize GBA resulted in the detection of active enzyme mainly in lysosomes. By confocal fluorescence microscopy, the ABP colocalized well with our antibody to GBA and was blocked by pre-incubation with the inhibitor CBE, showing the specificity of GBA labeling. In addition, the ABP colocalized significantly with the lysosomal membrane protein LAMP-1, which is approximately 5% of NHDFs, while the Man-R expressing NHDFs show a somewhat increased activity. * P < 0.01. C, Representative wet slab gel of at least three independent experiments shows the increased uptake of hrGBA by Man-R expressing NHDFs and LIMP II −/− fibroblasts, as compared to the Man-R negative fibroblasts. The addition of mannan reduces the hrGBA uptake to the same levels in all four cell lines, likely representing the uptake by non-specific, fluid-phase endocytosis. 1% of total MDW933-hrGBA that was added to the culture medium (input) was loaded for comparison. β-tubulin shows equal protein loading present in late endosomes and lysosomes. 18, 19 By CLEM we were able to determine that the highest levels of active GBA were present in lysosomes, based on the morphological characteristics of these compartments, while endosomes mostly appeared negative. Thus the LAMP-1-containing, ABP-negative compartments most likely represent late endosomes with GBA levels below the detection limit.
Subsequently, we aimed to follow the uptake of recombinant GBA and relate it to the localization of the endogenous enzyme using twocolor CLEM. To this end, hrGBA was in vitro labeled with ABP containing a green fluorophore, while the endogenous pool of GBA was in situ labeled with a red ABP. By confocal fluorescence microscopy we observed a significant overlap of green and red fluorescent signals, while there were also punctae positive for either fluorophore. Correlative microscopy showed that the overlapping green/red signals mainly localized to lysosomes, while the green dots represented endosomes containing hrGBA and the red dots lysosomes that had not been reached by endocytosed hrGBA. The observation that many, but not all lysosomes were reached by endocytosed hrGBA could be a technicality because of the imaging of sections instead of intact cells, or other factors such as the duration of uptake. Alternatively, an interesting possibility could be that there are different populations of lysosomes, some more and others less accessible by endocytosis.
Altogether, the imaging of GBA with ABPs in this correlative microscopy approach resulted in the localization of the enzyme to specific subcellular compartments, without the need for additional labeling. 20, 21 This method could be applied to model organisms as well, as these ABPs can be delivered to various tissues upon intravenous or intracerebroventricular injection in rodents. 13 
| MATERIALS AND METHODS

| Cell lines
| In situ labeling of GBA and fluorescence microscopy
Cells were grown to approximately 70% confluency on glass coverslips in 12-well plates. GBA was in situ labeled by adding MDW941
("red," BODIPY 573/612) to the culture medium at a concentration of 
| SDS-PAGE and Western blotting
Cells were lysed by the addition of ice-cold lysis buffer, that is, 
| Correlative microscopy
NHDFs were grown in 100 mm culture dishes to approximately 70%
confluency. GBA was in situ labeled with 5 nM MDW941 for 2 hours at 37 C, either with or without pre-incubation with 0.3 mM CBE for 16 hours as a control for the specificity of the signal. To check for autofluorescence, one dish was incubated for 2 hours with a similar 
| Labeling specificity in correlative microscopy
The specificity of the green and red fluorescent signals for hrGBA and endogenous GBA, respectively, was determined in the following way.
First of all, the in vitro labeling reaction was optimized to label over 99% of hrGBA, which was confirmed by an enzymatic activity assay to result in near absence of hrGBA activity. In this way, cross-labeling of hrGBA with red ABP was prevented during the in situ labeling.
Consistent herewith, no red ABP signal was detected in fibroblasts that lack GBA, because of a mutation in the receptor LIMP II, upon endocytosis of labeled hrGBA. Secondly, any unreacted green ABP was removed from the preparation before addition to the culture medium. SDS-PAGE analysis showed substantial reduction of unreacted ABP. Any remaining unreacted probe was not sufficient to result in detectable cross-labeling of endogenous GBA as determined by SDS-PAGE of the cell lysates. Finally, the uptake of ABP-labeled hrGBA in the presence of mannan did not result in a detectable green fluorescent signal in the cells by microscopy, indicating that the endogenous enzyme was not labeled with green probe. 
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